Sector News

Perrigo To Acquire Leading OTC Brands From GSK In All-cash Deal

June 3, 2015
Life sciences
(RTTNews) – Perrigo Company plc announced it has entered into an agreement to acquire a portfolio of over-the-counter brands from GlaxoSmithKline Consumer Healthcare, in connection with GSK’s commitments to divest these businesses in the context of the formation of a consumer health joint venture between GSK and Novartis.
 
The assets include: GSK’s NiQuitin nicotine replacement therapy business, primarily in the European Economic Area and Brazil, and Novartis’s legacy Australian NRT business, including the Nicotinell brand; Several assorted OTC brands including Coldrex across the EEA, and Panodil, Nezeril, and Nasin in Sweden; and Novartis’s legacy cold sore management products primarily in the EEA, marketed under the brand names Vectavir, Pencivir, Fenivir, Fenlips and Vectatone.
 
Perrigo expects the acquisition to be immediately accretive to its calendar 2015 adjusted earnings per share, excluding estimated intangible amortization and transaction-related costs. The transaction is expected to close in the third quarter of 2015.

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.